Genetically Proxied NLRP3 Inflammasome Downregulation and Cardiovascular Disease

Background: The inhibition of NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome is an emerging therapeutic strategy for atherosclerotic cardiovascular disease (ASCVD). Although early clinical trials demonstrate reductions in inflammatory biomarkers, whether these translate into cardiovascular benefit remains uncertain. We investigated the potential efficacy and safety of NLRP3 inhibition using human genetics. Methods: We developed a cis-genetic instrument for NLRP3 downregulation using C-reactive protein (CRP) associated variants (P<5 x 10^-8) within the NLRP3 locus (+/-100 kb of NLRP3 transcription start site) from 575,531 participants. Mendelian Randomization and colocalization analyses assessed the effect of the genetic instrument against gene expression of NLRP3 and other inflammatory mediators in immune cells, downstream inflammatory biomarkers, and pharmacodynamic responses to the NLRP3 inhibitor ruvonoflast. Two-sample Mendelian randomization assessed cardiovascular, cardiometabolic, and infectious outcomes, followed by phenome-wide analyses of 1,387 clinical outcomes. Results: Using 14 variants in the NLRP3 locus, we constructed a genetic instrument that corresponded to a 19% difference in circulating CRP between the extreme percentiles of its distribution. Colocalisation evidence suggested the effects on CRP to be driven by reduced NLRP3 expression in naive monocytes (PP.H4=98.7%). In accordance with the expected biological role of NLRP3, genetically proxied NLRP3 downregulation by the constructed instrument was associated with lower IL-18 (beta=-0.11; 95%CI, -0.14 to -0.08) and IL-6 (beta=-0.15; 95%CI, -0.17 to -0.12) and broadly similar pharmacodynamic effects to the NLRP3 inhibitor ruvonoflast across 8 biomarkers. Genetically proxied NLRP3 inhibition was associated with lower risk of recurrent pericarditis (OR per 19% decrease in CRP, 0.68, 95%CI, 0.58-0.80), but slightly elevated risk of coronary artery disease (OR, 1.06; 95%CI, 1.03-1.08) and peripheral arterial disease (OR, 1.10; 95%CI, 1.04-1.15) and no effect on ischaemic stroke (OR, 0.98; 95%CI, 0.94-1.02). The instrument was also associated with higher carotid-intima-media thickness and a worse cardiometabolic profile with increasing effects on blood pressure, waist-to-hip ratio, LDL cholesterol, and triglycerides. We found no associations with increased risk for prespecified infectious disease outcomes. Conclusions: A genetic proxy for NLRP3 inflammasome downregulation reproduced key molecular effects of pharmacological NLRP3 inhibition but was not associated with reduced ASCVD risk.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.16.26368176
Primary Topic
Inflammasome and immune disorders
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Genetically Proxied NLRP3 Inflammasome Downregulation and Cardiovascular Disease

Sizheng Steven Zhao, Benjamin P. Zuckerman, Marios K. Georgakis, Анастасія Осадча et al.
medRxiv
Inflammasome and immune disorders
preprint

Genetically Proxied NLRP3 Inflammasome Downregulation and Cardiovascular Disease

Sizheng Steven Zhao, Benjamin P. Zuckerman, Marios K. Georgakis, Анастасія Осадча, Lanyue Zhang, Panagiotis Zangas
preprint en

Abstract

Background: The inhibition of NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome is an emerging therapeutic strategy for atherosclerotic cardiovascular disease (ASCVD). Although early clinical trials demonstrate reductions in inflammatory biomarkers, whether these translate into cardiovascular benefit remains uncertain. We investigated the potential efficacy and safety of NLRP3 inhibition using human genetics. Methods: We developed a cis-genetic instrument for NLRP3 downregulation using C-reactive protein (CRP) associated variants (P<5 x 10^-8) within the NLRP3 locus (+/-100 kb of NLRP3 transcription start site) from 575,531 participants. Mendelian Randomization and colocalization analyses assessed the effect of the genetic instrument against gene expression of NLRP3 and other inflammatory mediators in immune cells, downstream inflammatory biomarkers, and pharmacodynamic responses to the NLRP3 inhibitor ruvonoflast. Two-sample Mendelian randomization assessed cardiovascular, cardiometabolic, and infectious outcomes, followed by phenome-wide analyses of 1,387 clinical outcomes. Results: Using 14 variants in the NLRP3 locus, we constructed a genetic instrument that corresponded to a 19% difference in circulating CRP between the extreme percentiles of its distribution. Colocalisation evidence suggested the effects on CRP to be driven by reduced NLRP3 expression in naive monocytes (PP.H4=98.7%). In accordance with the expected biological role of NLRP3, genetically proxied NLRP3 downregulation by the constructed instrument was associated with lower IL-18 (beta=-0.11; 95%CI, -0.14 to -0.08) and IL-6 (beta=-0.15; 95%CI, -0.17 to -0.12) and broadly similar pharmacodynamic effects to the NLRP3 inhibitor ruvonoflast across 8 biomarkers. Genetically proxied NLRP3 inhibition was associated with lower risk of recurrent pericarditis (OR per 19% decrease in CRP, 0.68, 95%CI, 0.58-0.80), but slightly elevated risk of coronary artery disease (OR, 1.06; 95%CI, 1.03-1.08) and peripheral arterial disease (OR, 1.10; 95%CI, 1.04-1.15) and no effect on ischaemic stroke (OR, 0.98; 95%CI, 0.94-1.02). The instrument was also associated with higher carotid-intima-media thickness and a worse cardiometabolic profile with increasing effects on blood pressure, waist-to-hip ratio, LDL cholesterol, and triglycerides. We found no associations with increased risk for prespecified infectious disease outcomes. Conclusions: A genetic proxy for NLRP3 inflammasome downregulation reproduced key molecular effects of pharmacological NLRP3 inhibition but was not associated with reduced ASCVD risk.

medRxiv
King's College London (GB), University of Manchester (GB), LMU Klinikum (DE), Dementia UK (GB), Institut für Schlaganfall- und Demenzforschung (DE), Ludwig-Maximilians-Universität München (DE)
Good health and well-being
Inflammasome and immune disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon